Tasigna is a new prescription drug from Novartis that has been used for the treatment of leukemia. It was recently discovered that Tasigna can cause acute atherosclerosis (narrowing of the arteries that supply blood to the heart). Novartis has intentionally concealed this dangerous side effect and many individuals who were prescribed Tasigna have suffered serious injury and even death as a result.
October 2021 Update: A new study published this month in the journal of Cardiology-Oncology identified a clear link between the use of Tasigna and vasospastic angina. This is yet another potentially dangerous side-effect linked to the low blood flow problems caused by Tasigna. Publication of this study came shortly after a new Tasigna "class-action” MDL was created in the U.S. District Court for the Middle District of Florida for the consolidated handling of the growing number of Tasigna lawsuits.
August 2021: On August 12, 2021, the United States Judicial Panel on Multidistrict Litigation (JPML) ordered the creation of a Tasigna class action lawsuit (technically called multi-district litigation or MDL) for claims involving this therapy.
Individuals who have suffered vascular damage as a result of their use of Tasigna may be entitled to financial compensation. Tasigna patients have already filed lawsuits against Novartis and there is now an Tasigna lawsuit MDL class action lawsuit in Florida. So federal lawsuits are consolidated into a MDL.
Our law firm is currently accepting cases from anyone who took Tasigna and was subsequently diagnosed with atherosclerosis or suffered a related type of cardiovascular injury (i.e., heart attack, stroke, etc.)About Tasigna
Tasigna (nilotinib) is a prescription drug that is used to treat chronic myeloid leukemia (CML). CML is a type of cancer that originates in the bone marrow and enters the blood. CML accounts for about 15% of all adult leukemia cases.
Tasigna is a relatively new drug that was developed by Novartis and approved for use in the treatment of CML in 2007. Since its original release, Tasigna has become a very profitable drug for Novartis. Tasigna works by blocking certain proteins that cause leukemia cancer cells to grow. Tasigna comes in capsules or pills that are taken orally and range in dosage from 50 to 200 mg. Most patients take a twice-daily 300 mg dose of Tasigna.Tasigna Linked to Atherosclerosis and Arterial Disease
Not long after Tasigna was first released in 2007, adverse incident reports and other evidence began to appear indicating that the drug could be causing serious cardiovascular problems in some patients. In 2011, the results of several studies reported that the use of Tasigna was causing some patients to develop accelerated atherosclerosis.
Atherosclerosis is a condition in which the arteries delivering blood from the heart become hardened and narrow. Normally, atherosclerosis is something that can develop gradually over time as a person gets older. However, the use of Tasigna was causing certain patients to develop atherosclerosis within a few months. Atherosclerosis can be very dangerous as it can result in serious cardiac and vascular events such as heart attack, or peripheral arterial disease.
The evidence linking Tasigna to rapid atherosclerosis prompted Canadian health authorities to issue a public warning about the risks of Tasigna.
In response, Novartis amended its Canadian prescribing information to include a warning that Tasigna can cause rapidly evolving vascular disease. Novartis deliberately chose not to add this warning to the prescribing information label for Tasigna in the U.S. In fact, the U.S. drug label for Tasigna still does not contain any information about the risk of atherosclerosis.
The medical literature suggest a strong probability that Tasigna is linked to atherosclerotic-related events, including stroke. While many patients taking Tasigna are at a higher risk for atherosclerosis, the a connection in many cases will be obvious because the medical literature describes an association between Tasigna and a rare from of accelerated atherosclerosis.
This is an important. Atherosclerosis is generally develops over an extended time, taking years to become an acute risk. Rapid progression or sudden aggravation of atherosclerosis is uncommon. Tasigna-induced atherosclerosis often develops much more quickly, giving doctors less time to diagnose and combat the condition.Tasigna Lawsuits Against Novartis
A growing number of people who developed rapid atherosclerosis from using Tasigna and suffered serious injuries have filed lawsuits against Novartis. The lawsuits allege that Novartis knew as early as 2010 (and probably earlier) that Tasigna caused accelerated atherosclerosis and related conditions. Novartis knowingly and intentionally failed to warn about these risks in the U.S. in order to protect its financial interests.
Specifically, plaintiffs' lawyers will contend that Navartis did warn Canadian doctors and patients of the harm of cardiac injuries but did not offer the same warning in the United States. Ultimately, this is the crux of what the Tasigna lawsuit is about.
Victims' lawyers will not argue at trial that there should have been a recall. Everyone gets that this is a life saving therapy. Some studies show that Tasigna is a better drug at fighting cancer than some of its competitors. But patients, particularly vulnerable cancer patients, have the right to know the risks and benefits of the drug they are taking. (Can anyone disagree?)
One of the very first Tasigna lawsuits against Novartis was a wrongful death case filed back in 2016. That case was eventually resolved in a confidential settlement and this led to a number of new Tasigna cases being filed across the country. To date, over 150 individual plaintiffs have filed Tasigna lawsuits. Most of these cases have been filed in New Jersey state courts.
A Tasigna class-action MDL is consolidated in Florida. The hope is that for a settlement in the Tasigna lawsuits Novartis after discovery is completed in these cases. As of August 13, 2021, there were only 18 Tasigna lawsuits pending in the MDL. But many more are expected to be filed in the near future.
What Are the Expected Settlement Amounts for Tasigna Lawsuits
It is early in the Tasigna class action lawsuits and it is difficult to estimate what the average settlement compensation might be in this litigation.
Certainly, the injuries are serious. The plaque from atherosclerosis is sometimes victims will need to deal with for the rest of their lives. But the injuries will vary wildly from cardiac disease to death. Our lawyers are usually quick to estimate average settlement amounts in mass torts. But it is too early for these lawsuits.Our Firm is Seeking New Cases from Anyone Injured by Tasigna
Our firm is actively seeking new cases from anyone who was prescribed Tasigna for the treatment of CML and subsequently developed atherosclerosis or any of the following related conditions or events:
- Heart attack
- Peripheral artery disease
- Myocardial ischemia
If you took Tasigna and later developed any of these conditions (or other cardiovascular conditions or events) you may qualify to file a lawsuit against Novartis, participate in the litigation, and receive settlement proceeds to compensate for your injuries.
See If You Qualify for a Tasigna Lawsuit
To see if you qualify to file a Tasigna lawsuit against Novartis, call our product liability lawyers today at 800-553-8082 or contact us online for a free case evaluation.